JPWO2019122065A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019122065A5
JPWO2019122065A5 JP2020534447A JP2020534447A JPWO2019122065A5 JP WO2019122065 A5 JPWO2019122065 A5 JP WO2019122065A5 JP 2020534447 A JP2020534447 A JP 2020534447A JP 2020534447 A JP2020534447 A JP 2020534447A JP WO2019122065 A5 JPWO2019122065 A5 JP WO2019122065A5
Authority
JP
Japan
Prior art keywords
hydrogen atom
pyrrolo
pyrimidin
dihydro
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020534447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506917A (ja
Publication date
Priority claimed from FR1771402A external-priority patent/FR3075795A1/fr
Application filed filed Critical
Publication of JP2021506917A publication Critical patent/JP2021506917A/ja
Publication of JPWO2019122065A5 publication Critical patent/JPWO2019122065A5/ja
Ceased legal-status Critical Current

Links

JP2020534447A 2017-12-21 2018-12-20 mTOR阻害剤化合物 Ceased JP2021506917A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1771402A FR3075795A1 (fr) 2017-12-21 2017-12-21 Nouveaux composes inhibiteurs de mtor
FR1771402 2017-12-21
PCT/EP2018/086074 WO2019122065A1 (fr) 2017-12-21 2018-12-20 Composes inhibiteurs de mtor

Publications (2)

Publication Number Publication Date
JP2021506917A JP2021506917A (ja) 2021-02-22
JPWO2019122065A5 true JPWO2019122065A5 (ko) 2023-06-13

Family

ID=62017455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020534447A Ceased JP2021506917A (ja) 2017-12-21 2018-12-20 mTOR阻害剤化合物

Country Status (16)

Country Link
US (1) US11518767B2 (ko)
EP (1) EP3727390B1 (ko)
JP (1) JP2021506917A (ko)
KR (1) KR20200103032A (ko)
CN (1) CN111918654A (ko)
AU (1) AU2018392761B2 (ko)
BR (1) BR112020012201A2 (ko)
CA (1) CA3086243A1 (ko)
CL (1) CL2020001686A1 (ko)
FR (1) FR3075795A1 (ko)
IL (1) IL275531B2 (ko)
MX (1) MX2020006436A (ko)
RU (1) RU2020123899A (ko)
SA (1) SA520412289B1 (ko)
SG (1) SG11202005868XA (ko)
WO (1) WO2019122065A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110407703A (zh) * 2019-08-02 2019-11-05 深圳振强生物技术有限公司 吲哚布芬杂质的制备方法
WO2023285926A1 (en) 2021-07-12 2023-01-19 Galderma Holding SA Synthesis of chiral substituted pyrazolopyrimidine compounds
WO2023031738A1 (en) 2021-08-31 2023-03-09 Galderma Holding SA Novel mtor inhibitor compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010160B1 (ru) 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
SI1951724T1 (sl) * 2005-11-17 2011-09-30 Osi Pharmaceuticals Llc Kondenzirani biciklični mTOR inhibitorji
CN101917999A (zh) 2007-11-07 2010-12-15 弗尔德里克斯制药股份有限公司 蛋白质运输的调节
EA018144B1 (ru) 2008-03-19 2013-05-30 Оси Фармасьютикалз, Инк. СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
US20140357651A1 (en) * 2011-05-04 2014-12-04 Yi Liu Combination pharmaceutical compositions and uses thereof
CA2835197A1 (en) * 2011-05-06 2012-11-15 Intellikine Llc Treatment of polycystic disease
RU2609208C2 (ru) * 2011-10-07 2017-01-31 Селлзоум Лимитед МОРФОЛИНО-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ БИЦИКЛИЧЕСКИХ ПИРИМИДИНМОЧЕВИНЫ ИЛИ КАРБАМАТА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
CA2833701A1 (en) * 2013-11-19 2015-05-19 Pharmascience Inc. Protein kinase inhibitors
KR102385482B1 (ko) * 2016-04-29 2022-04-12 메르크 파텐트 게엠베하 유기 전계발광 소자용 재료
FR3075794A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor

Similar Documents

Publication Publication Date Title
JP5911854B2 (ja) 有機化合物
EP2481739B1 (en) Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof
ES2929528T3 (es) Derivados de pirazolopirimidina como inhibidores de BTK para el tratamiento del cáncer
EP3781571B1 (en) N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
AU2011258465B2 (en) Bicyclic heteroaryl kinase inhibitors and methods of use
AU2009324894B2 (en) MLK inhibitors and methods of use
KR20160145796A (ko) BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
EP3555093A1 (en) Inhibitors of rip1 kinase and methods of use thereof
CN111867590B (zh) Atr激酶的杂环抑制剂
EP3976189B1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
AU2009322900A1 (en) Organic compounds
UA119848C2 (uk) Трициклічні гетероцикли як інгібітори білків бет
JP2009507032A (ja) 新規なイミダゾ系複素環
SG185644A1 (en) Macrocyclic compounds as trk kinase inhibitors
SG187548A1 (en) New aminopyrazoloquinazolines
EA032839B1 (ru) Конденсированные пентациклические производные имидазола
TWI811400B (zh) 經進一步取代之三唑并喹噁啉衍生物
TW202321261A (zh) 選擇性kras抑制劑
US11518767B2 (en) MTOR inhibitor compounds
JPWO2019122065A5 (ko)
AU2017350688A1 (en) Fused azaheterocyclic compounds and their use as AMPA receptor modulators
WO2021144440A1 (en) Quinoxaline derivatives as modulators of the glucocorticoid receptor
GB2504615A (en) Fused aminodihydrothiazine derivatives
CN116848103A (zh) 高活性hpk1激酶抑制剂